EICHORPublic-registry site landscape for NCT06267391, “Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes”, a Type 2 Diabetes Mellitus study sponsored by Endogenex, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT06267391 (registry record) |
| Study title | Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes |
| Official title | A Multicenter, Randomized, Double-blind, Sham-controlled Study for Assessing the Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes (ReCET Study) |
| Sponsor | Endogenex, Inc. |
| Condition(s) | Type 2 Diabetes Mellitus; Type2diabetes; Diabetes Mellitus, Type 2; Diabetes |
| Phase | NA |
| Listed sites | 45 |
| Site countries | United States, Australia |
Patient-friendly overview of this study: eichor.com/study/NCT06267391.
Eichor generates a preliminary site-risk snapshot for NCT06267391 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Type 2 Diabetes Mellitus trials
← Eichor home · All tracked trials · Type 2 Diabetes Mellitus studies · Weekly briefs
